Skip to Main Content

Paper Details

Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics.
Am Heart J
15
2024
CV death, GIP, GLP-1 receptor, HbA1c, MACE, People, atherosclerotic CV disease, atherosclerotic cardiovascular disease, coronary disease, diabetes, myocardial infarction, participants, people, peripheral artery disease, stroke, tirzepatide, type 2 diabetes
Author NameAffiliation
Deepak L BhattIcahn School of Medicine at Mount Sinai Health System
John B BuseUniversity of North Carolina
Naveed SattarUniversity of Glasgow
Bernard ZinmanUniversity of Toronto, Lunenfeld-Tanenbaum Research Institute and Mount Sinai Hospital
  • 1 - 4

Datasets

Release 1.2